Table 4.

Expression and mechanism of DDX5/17 in different cancers.

Cancer type	DDX5/17	DDX5/17expression	mechanisms/signaling	References
Breast cancer	DDX5/17	↑	DDX5/DDX17 are auxiliary activators of ERα DDX17 is a transcriptional coactivator of Sox2 and MDM2 DDX5 participates in β-catenin signaling pathway	(16, 68, 117)
Non-small-cell lung cancer	DDX5/DDX17	↑	Participate in β-catenin signaling pathway	(23)
Adult T-cell leukemia/lymphoma	DDX17/DDX5	↑	DDX17 participates in NF-κB signaling pathway and alternative splicing of CD44 DDX5 participates in Notch signaling pathway	(34, 78, 133)
Glioma tumor	DDX5/DDX17	↑	DDX5 participates in NF-κB signaling pathway; DDX17 inhibits glioma cell autophagy	(130, 146)
Prostate cancer	DDX5	↑	DDX5 is a transcriptional coactivator of AR	(73)
Colon cancer	DDX5	↑	Participate in β-catenin and NF-κB signaling pathway	(123)
colorectal carcinoma	DDX5	↑	Participate in β-catenin signaling pathway	(125)
Endometrial Cancer	DDX5	↑	Participate in β-catenin signaling pathway	(6)
Colon cancer	DDX5	↑	Participate in β-catenin signaling pathway	(126)
glioblastoma	DDX5	↑	Participate in NF-κB signaling pathway	(106)
colon adenocarcinoma	DDX5	↑	Participate in NF-κB signaling pathway	(106)
Thyroid cancer	DDX5	↑	Stimulate DNA DSB signaling cascade	(97)
Acute promyelocytic leukemia	DDX5	↑	Inhibiting ROS production	(144)
Esophageal squamous cell carcinoma	DDX5	↑	Regulating cell autophagy	(145)
Small cell lung cancer	DDX5	↑	Promote respiratory metabolism	(147)
Liver cancer	DDX5	↓	Regulating cell autophagy	(2)
Pancreatic ductal adenocarcinoma	DDX5	↓	Low expression of DDX5 is associated with poor prognosis in patients	(3)
pancreatic ductal adenocarcinoma	DDX17	↑	Participate in the alternative splicing of Caspase 9, mH2A1	(37)
hepatocellular carcinoma	DDX17	↑	DDX17 is a cosuppressor of Klf4 and promote the generation of the PXN-AS1-IR3 transcript	(18, 36)